PHP
ACLX

Parkman Healthcare Partners’s Arcellx ACLX Stock Holding History

Parkman Healthcare Partners’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-128,111
Closed -$8.35M – 93
2025
Q4 		$8.35M Sell
128,111
-21,737
-15% -$1.73M 0.8% 43
2025
Q3 		$12.3M Sell
149,848
-24,428
-14% -$1.76M 1.28% 27
2025
Q2 		$11.5M Buy
174,276
+106,886
+159% +$6.65M 1.32% 26
2025
Q1 		$4.42M Buy
67,390
+22,898
+51% +$1.55M 0.52% 55
2024
Q4 		$3.41M Sell
44,492
-22,000
-33% -$1.9M 0.45% 56
2024
Q3 		$5.55M Sell
66,492
-90,351
-58% -$6.02M 0.71% 48
2024
Q2 		$8.66M Buy
156,843
+245
+0.2% +$13.3K 1.16% 32
2024
Q1 		$10.9M Sell
156,598
-11,664
-7% -$740K 1.34% 30
2023
Q4 		$9.34M Sell
168,262
-35,220
-17% -$1.59M 1.32% 24
2023
Q3 		$7.3M Buy
203,482
+8,222
+4% +$283K 1.34% 25
2023
Q2 		$6.17M Buy
195,260
+47,614
+32% +$1.82M 1.07% 29
2023
Q1 		$4.55M Buy
147,646
+26,553
+22% +$805K 0.99% 39
2022
Q4 		$3.75M Sell
121,093
-18,782
-13% -$431K 1% 40
2022
Q3 		$2.63M Sell
139,875
-38,125
-21% -$730K 0.75% 51
2022
Q2 		$3.22M Buy
+178,000
New +$2.3M 1.19% 28

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Parkman Healthcare Partners's ACLX Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Arcellx (ACLX) in Q1 2026, closing a stake of 128,111 shares — an estimated $8.35M sold.

Parkman Healthcare Partners first reported a position in ACLX in Q2 2022 and held it in 15 quarters. The position peaked at $12.3M in Q3 2025. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • Parkman Healthcare Partners reported no remaining Arcellx position as of Q1 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 128,111 Arcellx shares in Q1 2026, an estimated $8.35M.
  • Parkman Healthcare Partners first reported a position in Arcellx in Q2 2022 and held it in 15 quarters.
  • Parkman Healthcare Partners's Arcellx position peaked at $12.3M in Q3 2025.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.